Automated Cell Culture Equipment Global Market Report 2025

The automated cell culture equipment market size has grown rapidly in recent years. It will grow from $2.07 billion in 2024 to $2.32 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. Growth in the historic period was driven by the increasing prevalence of cancer and rare diseases, rising demand for stem cell research, expanding government support for biotechnology, growth of contract research organizations, and the growing need for efficient laboratory automation.

The automated cell culture equipment market size is expected to see rapid growth in the next few years. It will grow to $3.61 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. Growth in the forecast period will be supported by the rising prevalence of cancer and rare diseases, increasing demand for stem cell research, greater government investment in biotechnology, continued expansion of contract research organizations, and a growing need for streamlined laboratory automation. Major trends expected in the forecast period include innovations in single-use and closed system technologies, advancements in bioreactors and incubators, progress in integrated cell processing platforms, ongoing research in automated workflows, and improvements in software-driven process control and monitoring.

The growing adoption of personalized medicine is expected to drive the growth of the automated cell culture equipment market in the coming years. Personalized medicine customizes medical treatment based on an individual’s genetic, lifestyle, and environmental factors, enabling more precise and effective care. This rising adoption is fueled by improved treatment outcomes, as therapies tailored to a patient’s genetic and biological profile can enhance efficacy and reduce adverse effects. Automated cell culture equipment supports personalized medicine by providing precise, high-throughput, and reproducible cell culture processes, facilitating the development of patient-specific therapies and tailored drug testing. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, up from six in 2022. This growth in personalized medicine adoption is contributing to the expansion of the automated cell culture equipment market.

Key companies in the automated cell culture equipment market are focusing on innovations that integrate automation for streamlined workflows, such as closed single-use consumable systems. These systems standardize processes, reduce contamination risks, minimize manual handling, and enable efficient scaling from research to clinical manufacturing. A closed single-use consumable system is a sterile, disposable setup that integrates multiple cell culture processes into one unit, ensuring reproducible and scalable workflows. For instance, in March 2025, Limula SA, a Switzerland-based biotechnology company, launched LimONE, an integrated system combining hardware, software, and single-use consumables to simplify and standardize cell culture and processing workflows. LimONE supports faster technology transfer, lowers labor and infrastructure costs, and enables scalable production of advanced cell therapies, including CAR-T and gene-edited stem cells, while ensuring reproducibility and regulatory compliance. This product launch strengthens Limula’s position in the automated cell culture equipment market.

In August 2023, Cell Microsystems, a U.S.-based biotechnology company, acquired Fluxion Biosciences for an undisclosed amount. The acquisition allows Cell Microsystems to expand its portfolio of advanced cell analysis solutions by integrating Fluxion Biosciences’ automated patch clamp and cell-based assay technologies, enhancing capabilities for cellular electrophysiology and rare cell research. Fluxion Biosciences specializes in automated patch clamp technology and cell-based assay tools for advanced cellular analysis.

Major companies operating in the automated cell culture equipment market are F. Hoffmann-La Roche Ltd, Hitachi Ltd., Merck KGaA, Panasonic Holdings Corporation, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Corning Incorporated, Lonza Group AG, Olympus Corporation, Sartorius AG, Eppendorf SE, Tecan Group Ltd., STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Hamilton Company, Greiner Bio-One International GmbH, Solida Biotech GmbH, Biostream International B.V., HiMedia Laboratories Pvt. Ltd., Kuhner Shaker AG, Cellexus International Ltd.

North America was the largest region in the automated cell culture equipment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in automated cell culture equipment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the automated cell culture equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The automated cell culture equipment market research report is one of a series of new reports that provides automated cell culture equipment market statistics, including the automated cell culture equipment industry global market size, regional shares, competitors with the automated cell culture equipment market share, detailed automated cell culture equipment market segments, market trends, and opportunities, and any further data you may need to thrive in the automated cell culture equipment industry. This automated cell culture equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Automated cell culture equipment refers to advanced laboratory systems designed to perform cell cultivation, maintenance, and monitoring with minimal human involvement. These systems incorporate technologies such as robotics, sensors, and software to improve reproducibility, efficiency, and precision in cell culture workflows. By automating routine processes, they enable high-throughput experimentation, lower the risk of contamination, and support complex research in drug development, regenerative medicine, and other life science fields.

The main product types of automated cell culture equipment include instruments, consumables, and software. Instruments refer to advanced laboratory devices used to automate essential cell culture steps such as seeding, incubation, monitoring, and harvesting, enhancing consistency, efficiency, and scalability. These systems function at different automation levels, including fully automated systems, semi-automated systems, and manual systems with automated features. Key applications include drug discovery and development, regenerative medicine, toxicology testing, vaccine development, and stem cell research. Primary end users include pharmaceutical companies, biotechnology companies, academic and research institutions, contract research organizations (CROs), and diagnostics and testing laboratories.

The automated cell culture equipment market consists of sales of automated cell culture systems, bioreactors, incubators, cell counters, liquid handling systems, cell imaging systems, consumables, reagents, culture plates, flasks, pipettes, tubing sets, sensors, and microcarriers. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.